Phillip Ley, MD
Surgical Oncology · Flowood, MSNPI 1790890499
Payments from drug & device makers
Across 97 payments — averaging $91.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hologic Inc$7K
- Smith+Nephew$473
- Amgen$327
- Myriad Genetic Laboratories, Inc.$290
- Carl Zeiss Meditec, Inc.$164
- Leica Microsystems Inc.$148
- plus $694 from 18 others
What the payments were for
- Consulting fees$6,66975%
- Speaking & faculty fees$3103%
- Food & beverage$1,91521%
- Gifts$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hologic Inc | 3 | $6,823 |
| Smith+Nephew | 39 | $473 |
| Amgen | 4 | $327 |
| Myriad Genetic Laboratories, Inc. | 12 | $290 |
| Carl Zeiss Meditec, Inc. | 4 | $164 |
| Leica Microsystems Inc. | 3 | $148 |
| Mayne Pharma Commercial LLC | 4 | $86 |
| Stryker | 2 | $86 |
| Endomagnetics Ltd | 2 | $82 |
| Tempus AI, Inc | 3 | $56 |
| Convatec Inc. | 2 | $53 |
| Bard Peripheral Vascular, Inc. | 3 | $52 |
| Puma Biotechnology, Inc. | 3 | $40 |
| Merit Medical Systems Inc | 3 | $39 |
| Focal Therapeutics, Inc. | 1 | $39 |
| Merck | 1 | $24 |
| Johnson & Johnson | 1 | $24 |
| Elucent Medical | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| KCI USA, Inc. | 1 | $18 |
| BD | 1 | $17 |
| Misonix Inc | 1 | $17 |
| Coopersurgical, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMLYGIC$310
- Mammotome elite$104
How this compares
Too few surgical oncology providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 17 | $5,034 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 15 | $3,147 |
| Tamoxifen Citrate | 104 | $1,280 |
| Letrozole | 92 | $1,185 |
| Doxycycline Hyclate | 19 | $179 |
| Mirtazapine | 11 | $137 |
| Levofloxacin | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Flowood
- Kelly BristerJackson$7K
- Wayne OrrJackson$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.